Category: Clinical Trials

FDA Advisory Committee Recommends approval of new Alzheimer’s drug Donanemab

If approved, donanemab would be the third FDA approved disease-modifying beta-amyloid treatment for Alzheimer’s disease.

/ June 23, 2024
Prescription Drugs

Generic Drugs: Are they different?

Standards in place for generic drugs should give consumers confidence that these products are just as effective as their brand-name equivalent.

/ May 23, 2024
EDTA structure. Chelation

We finally learn from TACT2 what we should have known two decades ago: Chelation therapy doesn’t work for heart disease

At SBM, we've long argued that chelation therapy for heart disease is quackery. An abstract presented recently finally confirmed that. Why did it take so long?

/ April 29, 2024
Turbo cancer?

COVID-19 vaccine-caused “turbo cancer” nonsense just keeps getting more turbocharged

No matter how implausible it is or how weak the evidence for it is, the myth that COVID vaccines cause "turbo cancer" just won't die. Quite the contrary, alas. Antivaxxers are—dare I say?—turbocharging it with bad science.

/ April 22, 2024

Fenbendazole is fast becoming the laetrile of the 2020s

Antivaxxers who "repurposed" deworming drugs like ivermectin and fenbendazole are peddling cancer "miracle cure" testimonials that remind me of laetrile and Stanislaw Burzynski. Truly, everything old is new again.

/ March 4, 2024

Adios Aduhelm

The controversial and never-proven-effective drug to treat Alzheimer's disease, aducanumab (Aduhelm) has been discontinued.

/ February 15, 2024
Macular degeneration

Pegcetacoplan (Syfovre™) for macular degeneration: an update

SBM's guest contributor and ophthalmologist, Dr. David Weinberg, provides an update on the phase 3 trials of pegcetacoplan for macular degeneration. The results are still disappointing.

/ January 11, 2024
EBM hierarchy

2023: The year that the evidence-based medicine (EBM) paradigm was weaponized against vaccines and public health

Evidence-based medicine (EBM) has been a very useful paradigm for assessing evidence in medicine. However, like any other framework, it can be misused, particularly when fundamentalist EBM methodolatry leads to its inappropriate application to questions for which it is ill-suited, a misuse that has been weaponized against public health during the pandemic.

/ January 1, 2024

Make Acupuncture Great Again

Calling a losing study a win. Making acupuncture great again.

/ December 19, 2023

Yet Another Alzheimer’s Drug

A third drug either FDA approved or showing clinical benefit for Alzheimer's disease confirms that the world of AD treatment has changed forever.

/ July 19, 2023